title: [Neuropsychiatric disorders in HCV-infected people--own observations].
abstract: Neuropsychiatric symptoms are commonly associated with chronic hepatitis C virus infection and its treatment. There are no Polish studies concerned this problem in patients during combination therapy (interferon and ribavirin).
  
  
  OBJECTIVE
  to examine the mood disorders an quality of life during the first 12 weeks of therapy.
  
  
  METHODS
  The following research instruments were used: the Present State Examination (PSE), The Beck Depression Inventory, The Montgomery Asberg Depression Rating Scale, SF-36, Hamilton Depression Rating Scale. ALT, AST, GGT activity, HCV viral load and genotype, histological activity index of the liver was also measured.
  
  
  RESULTS
  A group of 94 untreated patients (M=, K=) with hepatitis C was examined. 44 of them was examined secondly after 12 week of combination therapy. Depression disorders was observed in 4% pts before treatment and in 11% after 12 weeks therapy. In the group untreated patients there was two statistically significant correlations: between examined neuropsychiatric disorders and HCV viral load and necroinflammatory activity in the liver.
  
  
  CONCLUSIONS
  The mood disorders are not so common in the patients with hepatitis C and could have biological etiology. The interferon based therapy increase the frequency and intensity of them.
authors.affiliation: Katedra i Klinika Chorób Zakaźnych, Chorób Watroby i Nabytych Niedoborów Odpornościowych AM we Wrocławiu.
authors.forename: Marcin
authors.initials: M
authors.lastname: Czarnecki
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Inglot
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Małyszczak
authors.forename: Weronika
authors.initials: W
authors.lastname: Rymer
authors.forename: Grazyna
authors.initials: G
authors.lastname: Jańczak
authors.forename: Tomasz
authors.initials: T
authors.lastname: Pawłowski
authors.forename: Andrzej
authors.initials: A
authors.lastname: Gładysz
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003863:Depression / Q000139:chemically induced / Q000209:etiology*; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000523:psychology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000139:chemically induced / Q000209:etiology*; D011044:Poland; D011569:Psychiatric Status Rating Scales; D011788:Quality of Life; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin